The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005).

导出 OA

翻译打印收藏纠错

第一作者： Fangfang,Duan

第一单位： Department of Medical Oncology, Sun Yat-Sen University Cancer Center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangdong, 510060, Guangzhou, China.

作者： Fangfang,Duan ^[1] ; Muyi,Zhong ^[2] ; Yuyu,Ma ^[1] ; Chenge,Song ^[1] ; Lehong,Zhang ^[3] ; Ying,Lin ^[4] ; Zhiyong,Wu ^[5] ; Yuanqi,Zhang ^[6] ; Jiajia,Huang ^[1] ; Fei,Xu ^[1] ; Yanxia,Shi ^[1] ; Shusen,Wang ^[1] ; Zhongyu,Yuan ^[1] ; Wen,Xia ^[7] ; Xiwen,Bi ^[8]

作者单位： Department of Medical Oncology, Sun Yat-Sen University Cancer Center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangdong, 510060, Guangzhou, China. ^[1] Department of Breast Oncology, Dongguan People's Hospital, Dongguan, Guangdong, China. ^[2] Department of Breast Oncology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. ^[3] Department of Breast Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. ^[4] Department of Breast Oncology, Shantou Central Hospital, Shantou, Guangdong, China. ^[5] Department of Vascular Thyroid Breast Surgery, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China. ^[6] Department of Medical Oncology, Sun Yat-Sen University Cancer Center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangdong, 510060, Guangzhou, China. xiawen@sysucc.org.cn. ^[7] Department of Medical Oncology, Sun Yat-Sen University Cancer Center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangdong, 510060, Guangzhou, China. bixw@sysucc.org.cn. ^[8]

关键词 HER2 blockade therapy HER2-positive breast cancer Lapatinib Trastuzumab refractory

主题词抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);乳腺肿瘤(Breast Neoplasms);女(雌)性(Female);人类(Humans);治疗结果(Treatment Outcome)

DOI 10.1186/s12885-022-09399-2

PMID 35291977

发布时间 2022-05-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交